Loading…
ESMO 20th World Congress on Gastrointestinal Cancer has ended
Wednesday, June 20 • 14:50 - 15:20
Presentation of selected abstracts

Sign up or log in to save this to your schedule and see who's attending!

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
Funda Meric-Bernstam, et al., O-001
 
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew Zhu, et al., LBA-001
 
The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
Jen Ricke, et al., O-029

Wednesday June 20, 2018 14:50 - 15:20
Auditorium A, Level 0